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Abstract
Background: Differences in the management of coronary artery disease between men and
women have been reported in the literature. There are few studies of potential inequalities of
treatment that arise from a primary care context. This study investigated the existence of such
inequalities in the medical management of post myocardial infarction in older patients.
Methods: A comprehensive chart audit was conducted of 142 men and 81 women in an academic
primary care practice. Variables were extracted on demographic variables, cardiovascular risk
factors, medical and non-medical management of myocardial infarction.
Results: Women were older than men. The groups were comparable in terms of cardiac risk
factors. A statistically significant difference (14.6%: 95% CI 0.048–28.7 p = 0.047) was found
between men and women for the prescription of lipid lowering medications. 25.3% (p = 0.0005, CI
11.45, 39.65) more men than women had undergone angiography, and 14.4 % (p = 0.029, CI 2.2,
26.6) more men than women had undergone coronary artery bypass graft surgery.
Conclusion: Women are less likely than men to receive lipid-lowering medication which may
indicate less aggressive secondary prevention in the primary care setting.
Background
In the last decade, cardiovascular disease has become the
leading cause of death in women. [1] Concerns have been
raised about gender differences in both outcomes and in
access to medical care for cardiovascular disease.[2] Gen-
der differences have been documented in care sought for
myocardial infarction. Women are more likely to receive
in-hospital care from primary care physicians rather than
cardiologists. Patients admitted by cardiologists have a
significantly better survival rate than those admitted by
primary care physicians.[3,4]
Studies looking at the use of thrombolytic agents show
that they are consistently underused in eligible women
compared to men.[5] Beta-blockers and Aspirin are un-
der-prescribed in females who are post-MI.[6,7]Most in-
vestigations into gender differences in post-MI
pharmacological management originate from specialist
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care. Until recently there was little published data regard-
ing post-MI pharmacological management in primary
care. A study in a primary care setting revealed that wom-
en were twice as likely to have a diagnosis of hyperlipi-
demia, yet a higher percentage of men were on lipid-
lowering agents.[8]This study also revealed greater ASA
usage by males and no difference in beta-blocker usage,
although this was not a predefined outcome measure.
Gender differences may indicate the existence of troubling
inequalities in the delivery of health care by a publicly
funded system. Consequently, there is a need for further
studies to explore the existence of gender inequalities in
cardiovascular care in family practice, particularly with re-
spect to post myocardial infarction care. The purpose of
this study was to determine whether a clinically signifi-
cant gender bias exists in the medical management of post
myocardial infarction patients in an academic family
practice setting.
Methods
Our target population included all patients aged 60 years
and over who, in 2000, were registered patients at the
Family Practice Unit at Sunnybrook and Women's College
Health Sciences Centre with any history of prior myocar-
dial infarction. To narrow our search yet obtain a high
yield of patients, we conducted a search using the compu-
terized billing record using code 412 – the ICD-9 code for
coronary artery / atherosclerotic heart disease. Before the
study, we established that a sample of 120 males and 120
females with a prior history of MI would have an 80%
power at the 0.05 significance level to detect a 10% differ-
ence in pharmacological management. This was based on
an average 10% difference reported in previous studies.
The study was approved by the Research Ethics Board of
the Sunnybrook and Women's College Health Sciences
Centre.
We then conducted a pilot chart audit of 10 randomly se-
lected males and 10 randomly selected females, looking
for a history of MI. The charts were audited for demo-
graphic characteristics, co-morbid illnesses, modifiable
cardiovascular risk factors, pharmacological therapies and
non-pharmacological therapies. The primary outcome
measures were differences in the proportion of men and
women treated with ASA, ACE inhibitors, beta-blockers
and lipid-lowering agents. Secondary outcome measures
were non-pharmacological therapy and invasive interven-
tions.
This pilot yielded only 5 patients with a previous MI, from
which we determined that a random sample would not
yield the sample size required for the power of this study.
Hence, it was decided to audit all of the charts found un-
der billing code 412.
Analysis
The data were entered into Microsoft Excel 97. Continu-
ous data were analyzed by T-tests and categorical data by
chi-square and the Mantel-Haenszel test. Statistical signif-
icance was set at 0.05. All significance tests were two-sid-
ed. Outcome measures were differences in means and
proportions and 95% confidence intervals. Analysis was
done with EpiCalc 2000.
Results
Figure 1 summarizes the process by which the audit was
conducted. The audit yielded 966 charts – 530 males and
436 females – excluding patients who were deceased at
the start of the study or had left the practice. Of the 966
charts, 801 were found – 443 males and 358 females. Of
the 801 charts found, 223 patients had a history of prior
myocardial infarction – 142 males and 81 females.
The average age of the women was significantly greater
than that of the men. The average age was 79.6 for women
and 73.7 for men (Difference 5.9 years 95% C.I. 3.44–
8.36 p = 0.000004).
Table 1 summarizes the modifiable cardiovascular risk
factors. Women and men were similar with respect to
smoking status, hypertension, and hyperlipidemia. Co-
morbid illnesses including diabetes and congestive heart
failure occurred in similar proportions of men and wom-
en.
Table 2 summarizes the main outcome measures. No sta-
tistically significant differences in medical management
between men and women were found for the proportions
of males and females prescribed ACE inhibitors, beta-
Figure 1
METHODS
Total Charts
966
males – 530
females – 436
Charts found
801
males – 443
females – 358
Charts not found
165
males – 87
females – 78
N = post-MI patients
223
males – 142
females – 81
non-MI diagnosis
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blockers, ASA and anti-coagulants other than ASA. There
was a statistically significant difference in the proportion
of men taking lipid-lowering agents (Difference 14.6%:
95% CI 0.48–28.7 p = 0.047). This difference remained
after adjusting for the age imbalance between men and
women (Mantel-Haenszel age adjusted Odds Ratio
1.2918 95% C.I. 1.0348–1.6126, p = 0.0319).
Table 3 summarizes the non-pharmacological interven-
tions. There were statistically significant differences be-
tween men and women in utilization of angiography and
coronary artery bypass graft surgery. Specifically, 25.3% (p
= 0.0005, CI 11.45, 39.65) more men than women had
undergone angiography, and 14.4 % (p = 0.029, CI 2.2,
26.6) more men than women had undergone coronary ar-
tery bypass graft surgery.
Discussion
The results of this study among primary care patients with
a prior history of myocardial infarction found a statistical-
ly significant difference in the prescription of lipid-lower-
ing agents between males and females. The study failed to
detect a significant difference in pharmacological man-
agement between men and women in the use of ACE in-
hibitors, beta-blockers, nitrates and anticoagulants.
Women were older than men, but otherwise patient base-
line characteristics, modifiable cardiovascular risk factors
and co-morbid illness were similar, which further sup-
ports these results.
The reported difference in the use of lipid-lowering agents
is statistically significant and likely clinically relevant. The
point estimate of the difference was 14.6 %. This is higher
than the 10% level predetermined for clinical relevance.
The confidence intervals are wide but exclude a null result.
This result confirms the findings of Hippisley-Cox, who
reported a 10% difference in prescription rates of lipid-
lowering medication between men and women.[8] In this
study, similar proportions of men and women were doc-
umented to have hyperlipidemia, suggesting that women
are not being as aggressively targeted for secondary pre-
vention as are men.
Table 1: Patient Characteristics
All Patients
Age Females n = 81 Males n = 142 Difference and 95% Confidence Interval and 
p value
Range 60–105 60–91
Mean 79.62 73.65 5.9 years (95% C.I. 3.44–8.36) p = 0.000004
Variance 8.946 8.955
Modifiable risk factors/co-morbidity No. % No. %
Smoker 11 13.58 16 11.27 NS
Diabetic 17 20.99 36 25.35 NS
Hypertension 47 58.02 69 48.59 NS
Hyperlipidemia 35 43.21 70 49.30 NS
Congestive heart failure 27 33.33 32 22.54 NS
Table 2: Differences in medication use post MI, men and women
Medication Females n = 81 Males n=142 Difference and 95% Confidence Interval and p value
No. % No. %
ACE Inhibitor 46 57 79 56 NS
B-Blocker 58 72 107 75 NS
Lipid lowering agent 27 33 68 48 15 95% C.I. (0.48–28.7) p = 0.047
ASA 62 77 117 82 NS
Anticoagulant 14 17 16 11 NS
Nitrate 62 77 94 66 NSBMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/8
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A statistically significant difference between men and
women was demonstrated in non-pharmacologic man-
agement, notably angiography and bypass surgery. This
includes interventions that are most often offered by spe-
cialists and rarely if ever involve or are initiated by family
practitioners in Canada. This finding is consistent with
previous reports documenting gender differences in the
utilization of invasive procedures.[9,10]
There appeared to be a sub-optimal use of ACE inhibitors
with slightly more than 50% of men and women on these
medications. The results of the Heart Outcomes Preven-
tion Evaluation (HOPE) trial has been known for some
time but the final report was only published last year. Per-
haps this represents a delay in the implementation of cur-
rent data.[11]
This study has several limitations. The sample size of 223
(142 males, 81 females) post-MI patients is relatively
small, and there were more males than females. This is un-
likely to introduce a systematic bias. The study did not
reach the sample size requirements originally stated but
did have sufficient power to detect a 15% difference. The
proportions of men and women taking other medications
were very similar. By including the entire population of
patients under billing code 412, selection bias has been
essentially eliminated.
The data obtained for this study is limited to information
in the charts reviewed. This is likely one significant reason
for the small number of post-MI patients receiving cardiac
rehabilitation. The majority of charts indicated that the
patient had undergone rehabilitation through progress re-
ports. Different rehabilitation facilities may not have been
aware of their clientele's physicians resulting in no
progress reports being forwarded to their chart.
There was a significant number of missing charts totaling
165 charts. These may have been mis-filed or in the pos-
session of physicians or other staff. Attempts to locate
each chart in this study were made only once. No further
attempts to find the missing charts were made to avoid
any selection bias. As such, the number of missing male
charts (87) compared to missing female charts (78) was
not statistically significant.
Contraindications to specific medications were not inves-
tigated in this study. Such contraindications may explain
the low number of male and female patients on ACE in-
hibitors. In addition to the above-mentioned limitations,
this study was limited to the population of patients at the
Sunnybrook family practice, a population that consists
mainly of elderly patients.
While some of the results of this study provide reassur-
ance in the appropriateness of medical management of
post-MI, the ability to extrapolate these results to the gen-
eral population may be limited. Further studies examin-
ing gender differences in the treatment of cardiovascular
disease in primary care are required. Nonetheless, the re-
sults of this study suggest the need for improvement in the
management of all post-MI patients, as well as offering en-
couragement that effective post-MI management is being
applied relatively equally to both men and women.
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Table 3: MI Therapies
Females n = 81 Males n = 142 Difference and 95% Confidence Interval 
and p value
Therapy No. % No. %
Rehabilitation 13 16 41 29 NS
Angiography 24 30 78 55 25 % (95% C.I. 11.45–39.65) p = 0.0005
Angioplasty 14 17 26 18 NS
Thrombolysis 10 12 6 4 NS
Coronary Artery Bypass Grafting 14 17 46 32 15 % (95% C.I. 2.2–26.6) p = 0.029BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/8
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